Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 1-2, 1996, Pages 79-89

  Van Laar, Jan A M ^a,b   Rustum, Youcef M ^b   Van Der Wilt, Clasina L ^a   Smid, Kees ^a   Kuiper, Catharina M ^a   Pinedo, Herbert M ^a   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

5 Fluorouracil; Antitumor activity; Cisplatin; Leucovorin modulation; Tumor origin; Tumor size

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; THYMIDYLATE SYNTHASE;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL LINE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME; WEIGHT REDUCTION;

ADENOCARCINOMA; ANIMALS; ANTIDOTES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COLONIC NEOPLASMS; DRUG INTERACTIONS; FEMALE; FLUORODEOXYURIDYLATE; FLUOROURACIL; IMMUNOSUPPRESSIVE AGENTS; LEUCOVORIN; MICE; MICE, INBRED BALB C; WEIGHT LOSS;

EID: 0029820002     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050541     Document Type: Article

References (53)

1. Peters GJ, Van Groeningen CJ (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 2:469-480
2. Moertel CG (1994) Drug therapy - chemotherapy for colorectal cancer. N Engl J Med 330:1136-1142
3. Spiegelman S, Sawyer RC, Nayak R, Ritzi E, Stolfi RI, Martin DS (1980) Improving the antitumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc Natl Acad Sci USA 77:4866-4970
4. Santi, DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridine. Biochemsitry 13:471-481
5. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM (1994) Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 12:2035-2042
6. 2a in cultured colon adenocarcinoma xenografts. Cancer Chemother Pharmacol 30:423-432
7. Van der Wilt CL, Peters GJ (1994) New targets for pyrimidine antimetabolites for the treatment of solid tumors. I. Thymidylate synthase. Pharm World Sci 16:84-103
8. Scanlon KJ, Newman EM, Lu Y, Priest DG (1986) Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci USA 83:8923-8925
9. Van der Wilt CL, Van Laar JAM, Gyergyay F, Smid K, Peters GJ (1992) Biochemical modification of the toxicity and the anti-tumor effect of 5-fluorouracil and cis-platinum by WR-2721. Eur J Cancer 28A:2017-2014
10. Patt YZ, Boddie AW, Charnsangavej C, Ajani JA, Wallace S, Soski M, Claghorn L, Mavligit GM (1986) Hepatic arterial infusion with floxuridine and cisplatin: overriding importance of antitumor effect versus degree of tumor burden as determinants of survival among patients with colorectal cancer. J Clin Oncol 14:1356-1364
11. Sagaster P, Essel R, Teich G, Fritz E, Wasilewski M, Umek H, Dünser U, Mascher H, Micksche M (1994) Treatment of advanced colorectal cancer with folinic acid and 5-fluorouracil in combination with cisplatinum. Eur J Cancer 30A:1250-1254
12. Levi F (1994) Chronotherapy of cancer - biological basis and clinical application. Pathol Biol 342:3338-3341
13. De Vita VT (1983) The relationship between tumor mass and resistance to chemotherapy. Cancer 51:1209-1220
14. Jain RC (1989) Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81:570-576
15. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM (1975) A mouse colon-tumor model for experimental therapy. Cancer Chemother Rep 5:169-185
16. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM (1977) Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660-2680
17. Corbett TH, Bissery M, Mucci-Lo Russo P, Polin L (1991) 5-Fluorouracil containing combinations in murine tumor systems. Invest New Drugs 7:37-49
18. Eda H, Tanaka T, Ishitsuka H (1991) 5′-Deoxy-5-fluorouridine improves cachexia by a mechanism independent of its anti-proliferative action in colon 26 adenocarcinoma-bearing mice. Cancer Chemother Pharmacol 29:1-6
19. Iigo M, Nishikata K, Hoshi A (1992) In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin. Jpn J Cancer Res 83:392-396
20. 19F nuclear magnetic resonance spectroscopy. Cancer Res 54:4321-4326
21. Klohs WD, Steinkampf RW (1988) Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells. Cancer Res 48:3025-3030
22. Martin DS, Stolfi RL, Sawyer RC, Casper ES, Young CW (1983) Therapeutic utility of utilizing low doses of N-(phosphonacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res 43:2317-2321
23. Nadal JC, Van Groeningen CJ, Pinedo HM, Peters GJ (1988) In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma. Biomed Pharmacother 42:387-393
24. Nadal JC, Van Groeningen CJ, Pinedo HM, Peters GJ (1989) Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma. Invest New Drugs 7:163-172
25. Nord LD, Martin DS (1991) Loss of murine tumor thymidine kinase activity in vivo following 5-fluorouracil (FUra) treatment by incorporation of FUra into RNA. Biochem Pharmacol 42:2369-2375
26. Peters GJ, Braakhuis BJM, De Bruyn EA, Laurensse EJ, Van Walsum M, Pinedo HM (1989) Enhanced therapeutic efficacy of 5′deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumors in relation to 5-fluorouracil metabolising enzymes. Br J Cancer 59:327-334
27. Peters GJ, Van Dijk J, Nadal JC, Van Groeningen CJ, Lankelma J, Pinedo HM (1987) Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In Vivo 1:113-118
28. Peters GJ, Van Dijk J, Laurensse E, Van Groeningen CJ, Lankelma J, Leyva A, Nadal J, Pindeo HM (1988) In vitro biochemical and in vivo biological studies of uridine "rescue" of 5-fluorouracil. Br J Cancer 57:259-265
29. Peters GJ, Nadal JC. Laurensse EJ, De Kant E, Pinedo HM (1990) Retention of in vivo antipyrimidine effects of brequinar sodium (DUP-785; NSC368390) in murine liver, bone marrow and colon cancer. Biochem Pharmacol 39:135-144
30. Peters GJ, Kraal I, Pinedo HM (1992) In vitro and in vivo studies on the combination of brequinar sodium (DUP-895; NSC 368390) with 5-fluorouracil; effects of uridine. Br J Cancer 65:229-233
31. Peters GJ, Van der Wilt CL, Gyergyay F, Van Laar JAM, Treskes M, Van der Vijgh WJF, Pinedo HM (1992) Protection by WR-2721 of the toxicity induced by the combination of cisplatin and 5-fluorouracil. Int J Radiat Oncol Biol Phys 22:785-789
32. Peters GJ, Lankelma J, Kok RM, Noordhuis P, Van der Wilt CJ, Van Groeningen CJ, Meijer S, Pinedo HM (1993) Long retention of high concentrations of 5-fluorouracil in human and murine tumors compared to plasma. Cancer Chemother Pharmacol 31:269-276
33. Spears CP, Shahinian AH, Moran RC, Heidelberger C, Corbett TH (1982) In vivo kinetics of thymidylate synthetase inhibition in FUra-sensitive and -resistant murine colon adenocarcinomas. Cancer Res 42:450-456
34. Sugimoto Y, Oh-Hara T, Heike Y, Watanabe M, Nakatsuru Y, Ishiwaka T, Tsuruo T (1990) Establishment of highly metastatic variants of murine colon adenocarcinoma 26 under serum-free conditions. Int J Cancer 46:118-124
35. Tanaka Y, Eda E, Fujimoto K, Ishiwaka T, Ishitsuka H (1990) Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res 50:4528-4532
36. Tanaka Y, Eda H, Tanaka T, Udagawa T, Ishikawa T, Horii I, Ishitsuka H, Kataoka T, Taguchi T (1990) Experimental cancer cachexia induced by transplantable Colon 26 adenocarcinoma in mice. Cancer Res 50:2290-2295
37. Van Laar JAM, Van der Wilt CL, Treskes M, Van der Vijgh WYF, Peters GJ (1992) Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. Cancer Chemother Pharmacol 31:97-102
38. Van Laar JAM, Durrani F, Rustum YM (1993) Antitumor activity of the weekly iv push schedule of 5-fluoro-2′-deoxyuridine ± N-phosphonacetyl-L-aspartate in mice bearing advanced colon carcinoma 26. Cancer Res 53:1560-1564
39. Van der Wilt CL, Pinedo HM, Smid K, Peters GJ (1992) Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 52:4922-4928
40. 18F]-5-fluorouracil in mice: effects of route of administration, strain tumor and dose. Cancer Chemother Pharmacol 26:205-209
41. Weiss L, Ward PM (1988) Effects of metastatic cascades on metastatic patterns: studies on colon-26 carcinomas in mice. Int J Cancer 41:450-455
42. Winograd B, Boven E, Lobbezoo MW, Pinedo HM (1987) Tumor xenografts in the nude mice and their value as test models in anticancer drug development. In Vivo 1:1-14
43. Yusa K, Sugimoto Y, Yamori T, Yamamoto T, Toyoshima K, Tsuruo T (1990) Low metastatic potential of clone from murine colon 26 increased by transfection of activated c-erbB-2 gene. J Natl Cancer Inst 82:1633-1636
44. Van Kraanenburg-Voogd PJ, Keizer HJ, Van Putten LM (1978) Experimental chemotherapy of transplantable mouse colon tumors. Eur J Cancer 14 [Suppl]: 153-157
45. Peters GJ, Van Groeningen CJ, Laurensse E, Pinedo HM (1991) Thymidylate synthase from untreated human colorectal cancer and colonic mucosa: enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophosphate. Eur J Cancer 27:263-267
46. Tomayko MM, Reynolds CP (1989) Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 24:148-154
47. Boven E, Winograd B, Berger DP, Dumont MP, Braakhuis BJM, Fodstad O, Langdon S, Fiebig HH (1992) Phase II pre-clinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 52:5940-5947
48. Pinedo HM, Peters GJ (1988) Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6:1653-1664
49. Peters GJ, Jansen G (1996) Resistance to fluoropyrimidines. In: Schilsky RL, Milano GA, Ratain MY (eds) Principles of cancer drug pharmacology. Marcel Dekker, New York pp 543-586
50. Westerhof GR, Janssen G, Van Emmerik N, Kathman I, Rijkson G, Jackman AL, Schornagel JH (1991) Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res 51:5507-5513
51. Moldawer LL, Georgieff M, Lundholm K (1987) Interleukin 1, tumour necrosis factor (cachectin) and the pathogenesis of cancer cachexia. Clin Physiol 7:263-274
52. 18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity. A study for correlation with oncological results. Nucl Med Biol 23:333-342
53. Moghaddam A, Zhang HT, Fan TPD, Hu DE, Lees VC, Turley H, Fox SB, Gatter KC, Harris AL, Bicknell R (1995) Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92:998-1002